{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Parkinson Disease",
            "NStudiesAvail": 430108,
            "NStudiesFound": 16,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 16,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Xiqing Chai, Doctor",
                              "Ping Gu, Doctor",
                              "Hongxu Chen, Master"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Director",
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Enrolling by invitation"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 10, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The UPDRS was assessed to identify the severity of PD. It includes the four-scale structure with a reorganization of the various subscales. This four-scale structure are (Part I) nonmotor experiences of daily living (13 items), (Part II) motor experiences of daily living (13 items), (Part III) motor examination (18 items), and (Part IV) motor complications (six items). Each subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Changes of the Unified Parkinson's Disease Rating Scale (UPDRS)"
                        ],
                        "NCTId": [
                              "NCT03550183"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "Yang Xiao, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with adverse events"
                        ],
                        "NCTId": [
                              "NCT01446614"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Mya Schiess, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 18, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Adverse events include renal failure, liver failure, and hemolytic anemia.",
                              "Adverse events include renal failure, liver failure, and hemolytic anemia.",
                              "Adverse events include renal failure, liver failure, and hemolytic anemia.",
                              "Adverse events include renal failure, liver failure, and hemolytic anemia."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of allogeneic MSC therapy in patients with iPD as indicated by the presence of adverse events that are confirmed to be related to the therapy",
                              "Safety of allogeneic MSC therapy in patients with iPD as indicated by the presence of adverse events that are confirmed to be related to the therapy",
                              "Safety of allogeneic MSC therapy in patients with iPD as indicated by the presence of adverse events that are confirmed to be related to the therapy",
                              "Safety of allogeneic MSC therapy in patients with iPD as indicated by the presence of adverse events that are confirmed to be related to the therapy"
                        ],
                        "NCTId": [
                              "NCT02611167"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [
                              "Chadwick Prodromos, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2026"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Clinical monitoring of possible adverse events or complications"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety (adverse events)"
                        ],
                        "NCTId": [
                              "NCT05152394"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [
                              "Mya C Schiess, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 26, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale",
                              "Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale",
                              "Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale",
                              "Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale",
                              "Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale",
                              "Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale",
                              "Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale"
                        ],
                        "NCTId": [
                              "NCT04506073"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [
                              "Paresh k Doshi, MCh"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 30, 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Improvement in clinical condition of the patient assessed using UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) and Time Tests."
                        ],
                        "NCTId": [
                              "NCT00976430"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 1, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Positive trend is going to be detected in the overall score of the third part of the UPDRS scale(Unified Parkinson Disease Rating Scale) in the off- and in the on-period:neurological examination of patients in the dynamics is carried out in the morning after a 12 (24) - hour break in taking anti-Parkinsonian drugs \"off-state\", then one hour after they were taken \"on-state\".\n\nA score of 64 on the third part of the UPDRS scale represents the worst (total motor disability) with a score of zero representing (no disability).",
                              "Identification and assessment of the severity of non-motor symptoms is carried out using Non-motor Symptoms Questionnaire (PD NMS Questionnaire).A score of 30 represents the worst result with a score of zero representing (no disability).",
                              "The Pittsburgh Sleep Quality Index (PSQI) is used to assess sleep quality over the last month.The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.",
                              "The Epworth Sleepiness Scale (ESS) is used to measure daytime sleepiness.The ESS score can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'.",
                              "We use the Hamilton Depression Scale - Hamilton psychiatric rating scale for depression (HDRS) - to identify signs of depression. A score of 52 represents the worst result with a score of zero representing (no disability)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "motor symptoms change",
                              "non-motor symptoms change",
                              "sleep quality change",
                              "daytime sleepiness change",
                              "signs of depression change"
                        ],
                        "NCTId": [
                              "NCT04146519"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Chi-Tang Tu, Ph. D."
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 30, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Grading will be assessed using NCI CTCAE, version 5.0.",
                              "Safety of Mitocell will be assessed by routine physical examinations. Physical examination conducted in this study will include general appearance, skin, eyes, ears, nose,throat, head and neck, heart, chest and lungs, abdomen, extremities, lymph nodes, musculoskeletal,neurological, etc.",
                              "Clinical standard neurological examination by study investigator. Changes in motor function, sensory function, cranial nerve function (visual fields), cortical functions and reflexes are followed in the examination, scored as normal - abnormal without clinical relevance - abnormal with clinical relevance",
                              "Changes in blood pressure during the study , measured as systolic and diastolic blood pressure (in mmHg)",
                              "Changes in pulse rate during the study (in beats per minute)",
                              "Changes in body temperature during the study (in degrees celsius)",
                              "Changes in laboratory variables for haematology: hemoglobin (g/L). Result evaluated as \"normal\", \"abnormal without clinical relevance\" or \"abnormal with clinical relevance\"",
                              "Changes in laboratory variables for haematology: Platelet count (10E9/L). Result evaluated as \"normal\", \"abnormal without clinical relevance\" or \"abnormal with clinical relevance\"",
                              "Changes in laboratory variables for haematology: Cell counts (10E9/L) for total WBC, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Result evaluated as \"normal\", \"abnormal without clinical relevance\" or \"abnormal with clinical relevance\"",
                              "Changes in laboratory variables for haematology: INR (standardized prothrombin time) to determine the effects of oral anticoagulants on the clotting system. Result evaluated as \"normal\", \"abnormal without clinical relevance\" or \"abnormal with clinical relevance\"",
                              "Changes in laboratory variables for haematology: aPTT (sec) . Result evaluated as \"normal\", \"abnormal without clinical relevance\" or \"abnormal with clinical relevance\"",
                              "Safety of Mitocell will be assessed by any clinically significant abnormalities on ECG results as compared to Baseline. A standard 12-lead ECG was measured by using ECG machine that automatically measured PR, QRS, QT, and QTcF intervals.",
                              "Safety of Mitocell will be assessed by any clinically significant abnormalities on MRI scans as compared to Baseline."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Grading of Adverse Events",
                              "Routine physical examinations",
                              "Changes in physical examinations: clinical standard neurological examination [Safety of Mitocell]",
                              "Changes in vital signs: blood pressure [Safety of Mitocell]",
                              "Changes in vital signs: pulse rate [Safety of Mitocell]",
                              "Changes in vital signs: body temperature [Safety of Mitocell]",
                              "Changes in clinical laboratory safety screen: haematology - hemoglobin [Safety of Mitocell]",
                              "Changes in clinical laboratory safety screen: Platelet count [Safety of Mitocell]",
                              "Changes in clinical laboratory safety screen: white blood cell (WBC) counts [Safety of Mitocell]",
                              "Changes in clinical laboratory safety screen: International Normalized Ratio (INR) [Safety of Mitocell]",
                              "Changes in clinical laboratory safety screen: activated partial thromboplastin time (aPTT) [Safety of Mitocell]",
                              "Electrocardiogram (ECG)",
                              "Magnetic Resonance Imaging (MRI)"
                        ],
                        "NCTId": [
                              "NCT05094011"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "Abdallah Awidi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 30, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Side effects will be reported as Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, related TEAEs, severe TEAEs"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection"
                        ],
                        "NCTId": [
                              "NCT03684122"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [
                              "Djamchid Lotfi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 28, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "MDS-UPDRS Part II.",
                              "treatment-emergent Adverse Event.",
                              "SSAEs.",
                              "Incidence of thromboembolic events.",
                              "Incidence and risk of AEs of special interest (serious or non-serious), including peripheral events defined as, thromboembolism of the extremities.",
                              "Incidence and risk of AEs of special interest (serious or non-serious), including infections.",
                              "Incidence and risk of AEs of special interest (serious or non-serious), including hypersensitivities.",
                              "Clinically significant changes in CBC values.",
                              "Clinically significant changes in CMP values.",
                              "Clinically significant changes in Coagulation Panel values.",
                              "Clinically significant changes in Respiratory Rate.",
                              "Clinically significant changes in Heart Rate.",
                              "Clinically significant changes in Heart Rate.",
                              "Clinically significant changes in Blood Pressure.",
                              "Clinically significant changes in Weight in lb.",
                              "Clinically significant changes in general physical examination results.",
                              "Clinically significant changes in body systems physical examination results."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Changes in MDS-UPDRS Part II.",
                              "Incidence of treatment-emergent Adverse Event (TEAEs).",
                              "Incidence of treatment-emergent Serious Adverse Events (SAEs).",
                              "AEs of special interest (serious or non-serious) - thromboembolic events.",
                              "AEs of special interest (serious or non-serious) - thromboembolism of the extremities",
                              "AEs of special interest (serious or non-serious) - infections",
                              "AEs of special interest (serious or non-serious) - hypersensitivities.",
                              "Laboratory values. CBC",
                              "Laboratory values. CMP",
                              "Laboratory values. Coagulation Panel",
                              "Vital signs. - Respiratory Rate (breaths per minute)",
                              "Vital signs. - Heart Rate (beats per minute)",
                              "Vital signs. - Body Temperature (Fahrenheit )",
                              "Vital signs. - Blood Pressure (mmHg)",
                              "Weight in lb.",
                              "Physical examination results. General",
                              "Physical examination results. Body Systems."
                        ],
                        "NCTId": [
                              "NCT04928287"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "Djamchid Lotfi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 20, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II.",
                              "Treatment-emergent Adverse Event.",
                              "SSAEs.",
                              "Incidence of thromboembolic events.",
                              "Incidence and risk of AEs of special interest (serious or non-serious), including peripheral events defined as, thromboembolism of the extremities.",
                              "Incidence and risk of AEs of special interest (serious or non-serious), including infections.",
                              "Incidence and risk of AEs of special interest (serious or non-serious), including hypersensitivities.",
                              "Clinically significant changes in CBC values.",
                              "Number of Participants with changes in Laboratory CMP values",
                              "Number of Participants with changes in Laboratory Coagulation Panel values.",
                              "Number of Participants with Clinically significant changes in Respiratory Rate.",
                              "Number of Participants with Clinically significant changes in Heart Rate.",
                              "Number of participants with Clinically significant changes in Heart Rate.",
                              "Number of Participants with Clinically significant changes in Blood Pressure.",
                              "Number of Participants with Clinically significant changes in Weight in lb.",
                              "Number of Participants with Clinically significant changes in general physical examination results.",
                              "Number of Participants with Clinically significant changes in body systems physical examination results."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "1. Changes in the total score MDS-UPDRS Part II.",
                              "2. Incidence of treatment-emergent Adverse Event (TEAEs).",
                              "3. Incidence of treatment-emergent Serious Adverse Events (SAEs).",
                              "4. AEs of special interest (serious or non-serious) - thromboembolic events.",
                              "5. AEs of special interest (serious or non-serious) - thromboembolism of the extremities",
                              "6. AEs of special interest (serious or non-serious) - infections",
                              "7. AEs of special interest (serious or non-serious) - hypersensitivities.",
                              "8. Laboratory value Complete Blood Count (CBC)",
                              "9. Laboratory values Chemistry Metabolic Panel (CMP)",
                              "10. Laboratory values Coagulation Panel; Prothrombin time, Partial Prothrombin time, and INtern",
                              "11. Vital signs. - Respiratory Rate (breaths per minute)",
                              "12. Vital signs. - Heart Rate (beats per minute)",
                              "13. Vital signs. - Body Temperature (Fahrenheit )",
                              "14. Vital signs. - Blood Pressure (mmHg)",
                              "15. Weight in lb.",
                              "16. Physical examination results. General",
                              "17. Physical examination results. Body Systems."
                        ],
                        "NCTId": [
                              "NCT04995081"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "Djamchid Lotfi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Available"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [],
                        "NCTId": [
                              "NCT04772378"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 5, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Subjects will be evaluated by Neurological test",
                              "Subjects will be evaluated by UMSARS(Unified Multiple System Atrophy Rating Scale)",
                              "an increase in the thickness of the Retinal Nerve Fiber Layer(RNFL) checked from the High Definition-Optical Coherence Tomography examination(HD-OCT)",
                              "an increase in the Ganglion Cell Complex (GCC) checked from the High Definition-Optical Coherence Tomography examination(HD-OCT)",
                              "improvement of eyesight will be checked using LogMar Test",
                              "improvement of eyesight will be checked using Ishihara test",
                              "improvement of eyesight will be checked using VEP (Visual Evoked Potential)",
                              "improvement of eyesight will be checked using ERG (Electroretinogram)",
                              "The Brain will be checked to see Changes of MRI to see increased FDG Uptake",
                              "The Brain will be checked to see Changes of FGD-PET SCAN to see increased FDG Uptake",
                              "The Brain will be checked to see Changes of DaTScan to see increased FDG Uptake"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Changes of Clinical Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation",
                              "Changes of Clinical Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation",
                              "Changes of structures improvement of the eyes from Baseline to 1,3,6,9 and 12 months after second implantation",
                              "Changes of structures improvement of the eyes from Baseline to 1,3,6,9 and 12 months after second implantation",
                              "Changes of the eyesight from Baseline to 1,3,6,9 and 12 months after second implantation",
                              "Changes of the eyesight from Baseline to 1,3,6,9 and 12 months after second implantation",
                              "Changes of the eyesight from Baseline to 1,3,6,9 and 12 months after second implantation",
                              "Changes of the eyesight from Baseline to 1,3,6,9 and 12 months after second implantation",
                              "Imaging Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation",
                              "Imaging Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation",
                              "Imaging Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation"
                        ],
                        "NCTId": [
                              "NCT04876326"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [
                              "Rosaria Giordano, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "incidence of adverse events collected by clinical monitoring and performing routine laboratory tests"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "incidence of adverse events"
                        ],
                        "NCTId": [
                              "NCT01824121"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OverallOfficialName": [
                              "Rajiv Thakur, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "No longer available"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [],
                        "NCTId": [
                              "NCT04514952"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OverallOfficialName": [
                              "Baoyong Yan, Doctor",
                              "Ping Gu, Doctor",
                              "Yanyong Wang, Doctor",
                              "Lina Zhang, Master",
                              "Jun Zhang, Master"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Director",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "National Institutes of Health Stroke Scale (NIHSS) scores."
                        ],
                        "NCTId": [
                              "NCT01962233"
                        ]
                  }
            ]
      }
}